Emphasis on Drug Class (Anticoagulants, Heparin, and Others); Treatment (Surgery, Drugs, and Others); End-User (Hospitals, Specialty Clinics, Academic & CROs, and Others); and Region/Country
Global Deep Vein Thrombosis Market Size & ForecastThe global deep vein thrombosis market was valued at ~USD 650 million in 2023 and is expected to grow at a strong CAGR of around ~8% during the forecast period (2024-2032). Owing to advancements in imaging and diagnostic tools facilitated earlier and more accurate detection of DVT.
The market size of deep vein thrombosis across the globe is expanding because of several factors such as increased sedentary behavior, such as prolonged sitting or immobility, which raises the risk of DVT. Also, the rise in surgical procedures, especially orthopedic surgeries, increases the need for DVT prophylaxis and treatment.
February 2023: Bayer announced that first patients had been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of asundexian (BAY2433334), an investigational oral Factor XIa (FXIa) inhibitor, in patients with atrial fibrillation (AF) and patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), a temporary period of symptoms like those of a stroke.
This section discusses the key market trends that are influencing the various segments of the global Deep Vein Thrombosis market, as identified by our team of research experts.
Surgery Segment Transforming Industry
The surgery category is a significant driver of the Deep Vein Thrombosis (DVT) market, particularly in the Asia-Pacific region. Surgical procedures, especially major ones like orthopedic, cardiac, and cancer surgeries, significantly increase the risk of developing DVT. This elevated risk necessitates the use of prophylactic measures, including anticoagulant therapies and mechanical devices, to prevent the formation of blood clots. As the volume of surgeries continues to rise due to advancements in medical technology, increased accessibility to surgical care, and a growing aging population, the demand for DVT prevention and treatment solutions correspondingly escalates. This surge in surgical procedures, coupled with enhanced post-operative care protocols aimed at mitigating DVT risk, is a key factor propelling the growth of the DVT market in the region.
Asia-Pacific is Expected to Grow at a fastest CAGR During Forecast Period
The Asia-Pacific deep vein thrombosis (DVT) market is experiencing significant growth due to increasing awareness of the condition, rising healthcare expenditure, and a growing aging population. Technological advancements in diagnostic methods and treatment options, including novel anticoagulants and minimally invasive procedures, are driving market expansion. Countries like China, Japan, and India are leading in market development, fueled by the prevalence of risk factors such as sedentary lifestyles, obesity, and chronic diseases. Additionally, government initiatives to improve healthcare infrastructure and promote early diagnosis and treatment are further propelling the market forward. As a result, the Asia-Pacific DVT market is poised for robust growth in the coming years.
The global deep vein thrombosis market is competitive, with several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new type launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are Medtronic, Aspen Holdings, Novartis AG, Mylan N.V., GLENMARK PHARMACEUTICALS LTD., Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, GL Pharma, COBAPHARMA, Boehringer Ingelheim International GmbH
The global deep vein thrombosis market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to contact us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Executive Summary
4. Market Dynamics
5. Pricing Analysis
6. Global Deep Vein Thrombosis Market Revenue (usd Mn), 2022-2032f
7. Market Insights By Drugs Class
8. Market Insights By Treatment
9. Market Insights By End-user
10. Market Insights By Region
11. Value Chain Analysis
12. Competitive Landscape
13. Company Profiled
14. Acronyms & Assumption
15. Annexure
Analyzing the historical market, estimating the current market, and forecasting the future market of the global deep vein thrombosis market were the three major steps undertaken to create and analyze the adoption of global Deep Vein Thrombosis in major regions. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global deep vein thrombosis market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the global Deep Vein Thrombosis market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the global deep vein thrombosis market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as drug class, treatment, end-user, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the global Deep Vein Thrombosis market. Further, we conducted factor analysis using dependent and independent variables such as drug class, treatment, end user, and regions of the global Deep Vein Thrombosis market. A thorough analysis was conducted of demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the global deep vein thrombosis market sector across the globe.
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global Deep Vein Thrombosis market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to several factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2032 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global Deep Vein Thrombosis market. Data was split into several segments and sub-segments after studying various parameters and trends in the drug class, treatment, end-user, and regions in the global deep vein thrombosis market.
The current & future market trends of the global deep vein thrombosis market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the market’s overall attractiveness at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Q1: What is the global Deep Vein Thrombosis market’s current market size and growth potential?
Q2: What are the driving factors for the growth of the global Deep Vein Thrombosis market?
Q3: Which segment has the largest share of the global deep vein thrombosis market by drug class category?
Q4: What are the emerging technologies and trends in the global deep vein thrombosis market?
Q5: Which region will dominate the global deep vein thrombosis market?
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
